Lundbeck Inc. said the U.S. Food and Drug Administration will review its experimental drug for a rare epilepsy disorder.

Deerfield-based Lundbeck, the U.S. subsidiary of Denmark’s H. Lundbeck SA, said the drug, clobazam, is a therapy used to treat “seizures associated with Lennox-Gastaut syndrome in patients two years and older.” Known as “LGS,” the disease is typically diagnosed in childhood, the company said. Lundbeck hopes to eventually market the drug here under the trade name Onfi. Get the full story »